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Polymeric nanocapsules prevent oxidation
of core-loaded molecules: evidence based
on the effects of docosahexaenoic acid
and neuroprostane on breast cancer cells
proliferation
Jérôme Roy1*, Liliam Teixeira Oliveira1,2, Camille Oger3, Jean-Marie Galano3, Valerie Bultel-Poncé3, Sylvain Richard1,
Andrea Grabe Guimaraes2, José Mário Carneiro Vilela4, Margareth Spangler Andrade4, Thierry Durand3,
Pierre Besson5, Vanessa Carla Furtado Mosqueira2 and Jean-Yves Le Guennec1
Abstract
Background: Nanocapsules, as a delivery system, are able to target drugs and other biologically sensitive molecules
to specific cells or organs. This system has been intensively investigated as a way to protect bioactives drugs from
inactivation upon interaction with the body and to ensure the release to the target. However, the mechanism of
improved activity of the nanoencapsulated molecules is far from being understood at the cellular and subcellular
levels. Epidemiological studies suggest that dietary polyunsaturated fatty acids (PUFA) can reduce the morbidity
and mortality from breast cancer. This influence could be modulated by the oxidative status of the diet and it has
been suggested that the anti-proliferative properties of docosahexaenoic acid (DHA) are enhanced by pro-oxidant
agents.
Methods: The effect of encapsulation of PUFA on breast cancer cell proliferation in different oxidative medium
was evaluated in vitro. We compared the proliferation of the human breast cancer cell line MDA-MB-231 and of
the non-cancer human mammary epithelial cell line MCF-10A in different experimental conditions.
Results: DHA possessed anti-proliferative properties that were prevented by alpha-tocopherol (an antioxidant) and
enhanced by the pro-oxidant hydrogen peroxide that confirms that DHA has to be oxidized to exert its anti-proliferative
properties. We also evaluated the anti-proliferative effects of the 4(RS)-4-F4t-neuroprostane, a bioactive, non-enzymatic
oxygenated metabolite of DHA known to play a major role in the prevention of cardiovascular diseases. DHA-loaded
nanocapsules was less potent than non-encapsulated DHA while co-encapsulation of DHA with H2O2 maintained
the inhibition of proliferation. The nanocapsules slightly improves the anti-proliferative effect in the case of
4(RS)-4-F4t-neuroprostane that is more hydrophilic than DHA.
(Continued on next page)
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Conclusion: Overall, our findings suggest that the sensitivity of tumor cell lines to DHA involves oxidized metabolites.
They also indicate that neuroprostane is a metabolite participating in the growth reducing effect of DHA, but it is not the
sole. These results also suggest that NC seek to enhance the stability against degradation, enhance cellular availability,
and control the release of bioactive fatty acids following their lipophilicities.
Keywords: Nanocapsules, Docosahexaenoic, Acid, Neuroprostanes, Polyunsaturated fatty acids, Asymmetrical
flow-field-flow-fractionation, Breast carcinoma cells
Background
Breast cancer represents one of the major problems for
public health. Epidemiological studies have highlighted
environmental factors as having a major role in the
etiology of breast cancer. Genetic factors are obviously
involved in carcinogenesis, but diet, as an environmental
factor, is likely to have an influence on health [1], and
particularly on tumor emergence [2–4]. For 40 years,
differences in breast cancer incidence among women
over the world and the influence of migrations on this
incidence suggested that environmental factors such as
dietary fat may play a role in this disease [5, 6]. Some
epidemiological and experimental data have revealed
that PUFA, especially ω3 PUFA, inhibit the development
and the progression of breast cancer [7]. But this obser-
vation is still controversial [8–12]. In vivo studies
showed that the long chain ω3 PUFA α-linolenic acid
(ALA, 18:3n-3), eicosapentaenoic acid (EPA, 20:5n-3)
and docosahexaenoic acid (DHA, 22:6n-3) inhibit the
progression of breast cancer [13–15].
The inhibitory effect of n-3 PUFA seems to be corre-
lated with the number of skipped dienes [16]. Several
studies observed that the inhibition of mammary cancer
cells proliferation was more marked by a treatment with
DHA, than with EPA or ALA [17–22]. This suggests that
lipid peroxidation could be a prerequisite for PUFA to be
active [15, 17, 23–27]. Peroxidation of lipids followed by
transformation of the peroxides into secondary metabo-
lites may be a crucial step on the path leading to reduction
of cell proliferation rate [28].
DHA had already been formulated in different micro
and nanometrical delivery systems, such as liposomes [29]
nanoliposomes [30], cyclodextrins-polymer complex [31],
zein-prolamine-microcapsules [32] and carbohydrate-
based-microcapsules [33]. None of these systems have a
fluid oily core acting as reservoir, where PUFA could be
easily encapsulated and protected by a polymeric bio-
degradable wall. Furthermore, no investigations of their ef-
fects related to the oxidative status on tumor breast
cancer cell proliferation were presented to date.
Nanoencapsulation consists of creating small droplets
of liquid (core), which is packed inside a polymeric
wall, designed to protect the core from deterioration
and release it under desired conditions [34]. Also,
polymeric nanocapsules (NC) have been shown to
reinforce the biological effects of encapsulated drugs
[35–37], by increasing drug efficacy while reducing
toxicity [38]. This can be due to a better targeting of
the compounds to the cell [39] or/and a better protec-
tion of the encapsulated molecules against environmen-
tal factors such as light or enzymatic attack during
their transit through the digestive tract [40].
In the present study we hypothesized that NC could
protect the PUFA against oxidation to reach the breast
tumor cells in their active form. The effects of encapsula-
tion of DHA and 4F4t-NeuroP in NC were investigated
on mammary cancer cell proliferation following different
oxidative status in order to study the PUFA stability and
also the ability to act on cells proliferation. Poly-ε-
caprolactone (PεCL) nanocapsules filled with the PUFA
were designed herein in order to provide delivery systems
to be used orally. PεCL polymer is more appropriate to
resist to the adverse environment of the gastrointestinal
tract (GIT) than other biodegradable polyesters [41].
Furthermore, free-PUFA and PUFANC were tested in dif-
ferent oxidative conditions. Poly-ε-caprolactone (PεCL)
NC loaded with DHA or 4(RS)-4-F4t-neuroprostane
(4F4T-NeuroP), an oxygenated metabolite derived from
DHA, were prepared by polymer deposition followed by
solvent displacement [42]. The NC were characterized by
dynamic light scattering (DLS), atomic force microscopy
(AFM) and asymmetrical flow field flow fractionation
(AsF4) coupled to multi-angle laser light scattering detector
(MALLS), DLS and UV–vis detectors. The capacity of NC
to protect drugs against oxidation was evaluated in vitro.
To do so, we took advantage of the need of DHA to be
oxidized in order to inhibit tumor cell proliferation. Also,
we evaluated if some pharmacological beneficial effects of
NC [37–39, 43] are mediated by a protection of the encap-
sulated drugs against oxidation. We also tested if 4F4t-
NeuroP, the most abundant product of non-enzymatic oxi-
dation of DHA [44] also has anti-proliferative properties.
Results
Nanocapsules development and characterization
The DHA and 4F4t-NeuroP were encapsulated in the
oily core of polymeric (PεCL) NC. Table 1 shows the
main physicochemical characteristics of the optimized
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NC formulations. Using two sizing methods (DLS in liquid
state and AFM in argon dried state) for the determination
of particle size distribution gave very similar results, with
no statistical difference between both sizing methods. This
confirmed the colloidal nature of the polymeric NC and
the narrow dispersion of the NC population prepared from
DHA and 4F4t-NeuroP using the polymer deposition
followed by solvent displacement method [45]. The accur-
ate mean sizes were measured because NC average diame-
ters were in the best resolution range of DLS and AFM
techniques, 3–1000 nm and 0.5–1000 nm, respectively
[46]. Mean sizes of 150–180 nm were obtained with the
blank-NC, DHA, DHA+VitE and 4F4t-NeuroP loaded NC
(Table 1) with a monodispersed profile of size distribution.
However, a significant increase (P < 0.05) in mean
size was evidenced by the DLS and AFM for the
DHA +H2O2 NC formulation (Table 1). The general
aspect of PUFA core-loaded NC height images in
AFM is homogenous and monodisperse, at the excep-
tion of DHA + H2O2 NC (Fig. 1a). The AFM phase
images show the leaky and heterogeneous nature of
DHA +H2O2 NC compared with the three other NC
formulations. Furthermore, the NC deformation,
shrinking and leakage was evidenced under the tip
pressure along with the probe scanning in tapping
mode (not shown). Fractionation of the nanoparticle
sample by the AsF4 can be presented in fractograms
(Fig. 1b), where the most intense peaks were selected
for further analysis of nanoparticles by DLS and
MALLS detectors. The fractograms of ASF4 coupled
to DLS show that all NC formulations were highly
homogenous in size, even with the encapsulation of
PUFA compared to unloaded NC filled only with
medium chain triglycerides (data not shown). How-
ever, AS-F4-MALLS analysis of DHA + H2O2 NC
showed more heterogeneity in size distribution and
the presence of larger aggregates (Fig. 1b) compared
with DHA NC. All three sizing techniques (AFM,
DLS, ASF4-MALLS) evidenced the same increase in
sizes after inclusion of hydrogen peroxide in NC for-
mulation compared to DHA NC (Table 1). No sig-
nificant difference in size was observed after the
additional loading of VitE in DHA NC formulation.
The summary of the results is shown in Table 1.
DLS provides the Z-average hydrodynamic diameter
and hydrodynamic radius by calculation and the
MALLS gives the geometric diameter calculated from
the direct determination of gyration radius (mean
square root). The ratio Rg/Rh allows estimating the
shape factor [46]. As a result of fractionation, a significant
reduction in mean sizes was observed because larger size
and aggregated nanoparticles were removed and only the
most abundant NC population were analyzed. The values
of the shape factors indicate that blank NC, NC-DHA,
NC-DHA +VitE and 4F4t-neuroP are soft spheres with
values of shape factors closer to 0.977, for a hollow sphere
[46]. This is in accordance with a vesicular nature of those
NC with oil filled core. On the other hand, DHA+H2O2
NC differs greatly from the spherical shape, which sug-
gests worm-like structures, with shape factors approxi-
mately of 2. This suggests coalescence of DHA+H2O2
NC and system instability under minimal pressure stress
while macroscopic observations of the NC suspension
samples in basal condition did not indicate any sign of
flocculation or aggregation.
The zeta potentials of NC filled with medium chain
triglyceride (blank-NC), Miglyol oil, and of those
filled with PUFA were not significantly different, in-
dicating that the PUFA were successfully encapsu-
lated and that they had a weak influence on surface
charges (Table 1). In the opposite, when VitE was
co-encapsulated with DHA, it induced a significant
Table 1 Physicochemical characterization of the PUFA nanocapsules using different methods before and after sample fractionation
Before fractionation After fractionation
Formulations AFM DLS Mean Mean ζ Zeta AsF4-DLS AsF4-MALLS Rg/Rh
mean size Z-average size PdI Potential ± SD (mV) Z-average Dg (nm) (shape factor)
± SD (nm)a Dh ± SD (nm) Dh (nm)
NC PCL 193 ± 28 157 ± 3 0.122 −28.9 ± 1.4 124 ± 9 111 ± 1 1.152
NC PCL-DHA 183 ± 26 161 ± 1 0.113 −29.7 ± 0.7 145 ± 31 116 ± 7 1.032
NC PCL-DHA + Vit E 203 ± 42 179 ± 3 0.089 −20.6 ± 0.7b 170 ± 25 128 ± 15 0.976
NC PCL-DHA + H2O2 236 ± 59 207 ± 2b, c 0.160 −32.4 ± 1.6c 144 ± 31 205 ± 13c 1.838c
NC PCL-4F4t 194 ± 52 161 ± 3 0.111 −29.5 ± 1.6 120 ± 18 112 ± 9 1.218
ζ Zeta Potential, AFM atomic force microscopy, AsF4 asymmetrical flow-field-flow- fractionation, DLS dynamic light scattering, PdI polydispersity index, Dh z- verage
hydrodynamic diameter, Dg mean geometric diameter (Dg = 2*Rg*0.775), LDA Laser Doppler Anemometry, MALLS Multi Angle Laser Light Scattering Detector, PεCL
poly-ε-caprolactone, Rg radius of gyration (root mean square radius), Rh hydrodynamic radius, EE encapsulation efficiency, PdI polydispersity index, Dh z-average
hydrodynamic diameter, Dg mean geometric diameter (Dg = Rg*2*0.775), Rg radius of gyration (root mean square radius), Rh hydrodynamic radius. adetermined
by the measurements of at least 40 particles in the height images; mean values taken from the selection of the most intense peak in the fractogram. Shape factor
calculation (Mathaes et al., 2013). bSignificant difference (p <0.05) from control formulation; c Significant difference (p <0.05) from non-oxidized
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Fig. 1 (See legend on next page.)
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increase in zeta potential in comparison with DHA encap-
sulation alone (from − 29.7 ± 0.7 mV to − 20.6 ± 0.7 mV)
(Table 1).
Effects of DHA on cell growth
DHA inhibited the growth of MDA-MB-231 cancer cells
in a dose-dependent manner (Fig. 2a) while it had no
effect on the immortalized epithelial MCF-10A cells
(Fig. 2b). The inhibition of cancer cells proliferation by
DHA was prevented in the presence of VitE and en-
hanced with H2O2 in the medium (Fig. 2a). It has to be
noted that the inhibition of cancer cell proliferation does
not exceed 55 % at the highest concentration tested
(100 μM). The immortalized MCF-10A cells were in-
sensitive to DHA whatever the environmental oxidative
status (Fig. 2b).
Effects of DHA encapsulation on cell proliferation
Encapsulation of DHA alone or in association with an
anti-oxidant or a pro-oxidant modified its effects on the
proliferation of cancer cell line MDA-MB-231. DHA in
NC at concentrations lower than 30 μM increased cell
proliferation when compared to free DHA (Fig. 3a).
However, above 30 μM both free and encapsulated DHA
reduced MDA-MB-231 cell proliferation. In contrast, in
the presence of VitE, DHA encapsulation below 50 μM
did not modify the proliferation (Fig. 3b) while free
DHA at high concentrations (100 μM) reduced cell pro-
liferation by approximately 30 %. With H2O2 (Fig. 3c)
NC potentiated the anti-proliferative properties of DHA
at all the concentrations tested.
Effect of DHA-derived oxygenated metabolites on cell
proliferation
The oxidative status (presence of VitE or H2O2) of the
medium surrounding DHA appears to influence the effects
of the PUFA on cell proliferation. This suggests that the
formation of oxygenated metabolites can be involved. To
investigate this hypothesis, we used 4F4t-neuroP, an oxy-
genated metabolite of DHA, which is the most common
non-enzymatic oxygenated metabolite of DHA [44]. This
metabolite was thus synthesized [47] and tested on
cultured cells. Free 4F4t-neuroP had a slight potentiating
effect on cell proliferation at concentrations up to 10 μM
(Fig. 4) in breast cancer cells and had no effect in normal
cells (date not shown). Encapsulation of 4F4t-neuroP
significantly increased (p < 0.05) the anti-proliferative effect
at concentrations above 1 μM (Fig. 4).
Discussion
PCL is a suitable biodegradable polymer to resist the
GIT acid and alkaline environment compared to more
Fig. 2 Effect of DHA+ VitE, DHA and DHA + H2O2 on the growth of
breast carcinoma cell line MDA-MB-231 (a) and normal immortalized
breast epithelial cells MCF-10A (b). The cells were exposed to 0.3, 1, 3,
10, 30, 50, 100 μM and after 4 days, cell proliferation was measured by
MTT 0.5 mg/mL method (see Materials and methods). The relative cell
proliferation (absorbance of test wells) was expressed as a percentage
of the control (100 %) that was not treated with DHA (absorbance of
control wells without DHA or with NC alone). Points are expressed as
the mean values relative to control for three separate experiments,
each set up in triplicate wells
(See figure on previous page.)
Fig. 1 Characterisation of nanocapsules in the different experimental conditions. a Atomic Force Microscopy (AFM) images of height (left) and phase
(right) showing the Differences in The PUFA-loaded NC size dispersion and Morphology (scan Sizes are 10×10 μm). b Fractograms Of the different PUFA
nanocapsules After Asymmetrical-Flow-Field-Flow-Fractionation (AsF4). Black Dots represent Detection by DLS (Z-average hydrodynamic diameter) and the
blue trace represents UV detection. Green dots (DLS) and red full line (UV-intensities) refer to unloaded PεCL NC for comparison in each graph. The inserts
represent the traces of 92o angle analysis from peak selection zones (brown bars) where the MALLS Analysis was performed to provide radius of gyration
(Rg, Root mean square radius) (red Line and left Y axis) and detector signal intensity in volume (blue Line and right Y axis). The First peak at short retention
times is the void volume
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hydrophilic and fast degradable ones, PLA and PLGA
[41]. The physicochemical characterization of NC
showed that DHA and 4F4t-NeuroP were successfully
encapsulated in the oily core of this polymeric system.
The NC average sizes are in the range of 150–200 nm
with no significant difference between DHA and 4F4t-
NeuroP NC (Table 1). Oppositely, including H2O2 in the
NC formulation induced a strong alteration of the stabil-
ity of the NC polymeric wall, which consequently
induced leakage of the core under minimal pressure
stress. The NC filled with VitE showed a reduced zeta
potential in modulus, thus a lower charge potential at
the NC surface (Table 1). This probably had an influence
on the exposure of the negatively charged groups at the
NC surface. Oxidation mediated by H2O2 could lead to
the peroxidation of PUFA with the generation of
Fig. 4 Effect of free or encapsulated 4(RS)-4-F4t-neuroprostane on the
growth the breast carcinoma cell line MDA-MB-231. Cells were exposed
4 days to 0.3, 1, 3, 10, 30, 50 and 100 μM then cell proliferation
was measured by the MTT method (see Materials and methods).
The relative cell proliferation (absorbance of test wells) was expressed
as a percentage of the control (line 100 %) that was not treated with
4(RS)-4-F4t-neuroprostane (absorbance of control wells with vehicle
or NC with vehicle). * Significantly different between the free and
encapsulated substance at the same concentration, at P < 0.05. Data
points are mean ± SEM of three separate experiments, each one
performed in three wells
Fig. 3 Differential effects of free or encapsulated DHA on the growth
the breast carcinoma cell line MDA-MB-231. Cells were exposed to free
DHA (a), free DHA+ VitE (b) and free DHA+H2O2 (c) over a 0.3–100 μM
concentration range or an equivalent volume of ethanol (delivery
vehicle) as a control. The same conditions were used with nanocapsules
containing the same substances. The MTT assay was performed after
4 days culture. The relative cell proliferation (absorbance of test wells).
was expressed as a percentage of the control (line 100 %) that was not
treated with DHA (absorbance of control wells without DHA or
with NC alone). Results are expressed as absorbance, normalized
as percent of control (100 %). * Significantly different between the
free and encapsulated substances at the same concentration, at
P < 0.05. Data points are mean ± SEM of three separate experiments,
each one performed in three wells
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oxygenated metabolites. As oxygenated metabolites gen-
erally show high polarity compared to their precursors
this would impart negative charges to the NC surface.
VitE co-encapsulation with DHA is likely to protect
PUFA against peroxidation, thus maintaining lower
negative values of zeta potential (Table 1). Also, the
polymeric membrane probably increases the protection
of the fatty acids against oxidation and also reduces the
interaction with cells at selected concentrations.
In this paper, we challenged the hypothesis that NC
core-loaded PUFA are protected from peroxidation.
Indeed, it is known that the anti-proliferative effects of ω3
PUFA are prevented by VitE [48] while they are enhanced
by pro-oxidants [25, 49] that generate oxygenated metabo-
lites. To show that, we took advantage of the well-known
effect of those oxygenated metabolites of ω3 PUFA on
cancer cells proliferation [20, 25, 26, 48, 50]. In this study
we observed an effect of the oxidative status of DHA on a
breast cancer cell line in vitro. The oxidative status had a
selective role on cancer cell proliferation compared to
non-cancer cells (MCF-10A). Similar findings have been
reported in the presence of antioxidant, with an increase
in the proliferation of cancer cells [15, 51, 52]. Other
authors had already reported that DHA impaired breast
cancer cell growth and survival by enhancing metabolic
stress, particularly by down-regulating total glycolytic
metabolism, while not influencing a non-cancer breast
epithelial cell line (MCF-10A) [53]. In the first part of the
present study, we confirmed a DHA dose-dependent
decrease in MDA-MB-231 cells proliferation, a property
not found in the non-cancer human mammary epithelial
cell line MCF-10A. This effect was reinforced in the pres-
ence of H2O2 and prevented in the presence of VitE. The
IC50 of free DHA +H2O2 was approximately 38 μM in
cancer cells and not determined in normal cells (no effect
at 100 μM), indicating a good selectivity toward cancer
cells in vitro.
When encapsulated, DHA at concentrations below
30 μM increased the proliferation of cancer cells, while
encapsulation with VitE at comparable concentrations
had no effect.
DHA is very hydrophobic (log P = 6.8) and its release in
culture medium is probably delayed and reduced by the
high partition coefficient in favor of the NC oily core, even
after incubation for 4 days with the cells (Fig. 5). This can
explain the reduced DHA anti-proliferative effects on
cancer cells. A free fraction of intact DHA (not oxidized)
released by the DHA-NC formulation could explain its ac-
tivity similar to the free air-oxidized DHA (oxidized in the
air) at the highest concentrations in vitro (above 50 μM).
In the opposite, 4F4t-NeuroP is a much more polar fatty
acid (log P = 2.5) and is probably released from NC faster
than DHA, which could explain its improved antiprolifer-
ative effect compared to the free 4F4t- NeuroP at concen-
trations of 10–50 μM. The slow release of 4F4t-NeuroP
from NC into the culture medium probably maintains its
activity for longer times, warranting the anti-proliferative
effect upon tumor cell. Also, the NC polymeric membrane
probably increases the protection of the 4F4t-NeuroP
against oxidation, which could explain the absence of
effect for low concentration for free-4-F4t-NeuroP. Thus
the difference between the activities of DHA and its non-
enzymatic oxygenated metabolite in NC form could be
attributed to their difference in lipophilicities (log P) and
affinities for the NC oily core that further influences their
release rate in the cell medium.
The results obtained with encapsulated H2O2 are difficult
to interpret since H2O2 by itself had an effect on NC.
H2O2 induced degradation of the polymeric NC wall
makes difficult the interpretation of the data. The disrup-
tion of NC wall probably increases the availability of DHA
to be oxidized by H2O2, which increases the anti-
proliferative effect of DHA in the presence of H2O2. In that
case, the investigation of the different mechanism of in-
ternalization of nanostructures, similar to trojan horse type,
via endocytic pathways, could explain an increased delivery
of the amount of oxidized DHA metabolites inside cells.
In the opposite to H2O2, such interactions of DHA
with NC were not found in absence and presence of
VitE. Knowing that DHA has to be oxidized to inhibit
proliferation [25, 49], it is likely that NC protect the fatty
acid against oxidation. Indeed, it is known that preparing
Fig. 5 Chemical structures of DHA, 4(RS)-4F4t-neuroprostane and D-alpha-tocopherol (VitE) and the calculated lipophilicity (Log P) using ACD/Labs
Software v.14.03
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a DHA solution in a physiological saline solution under
the normal atmosphere containing oxygen leads to the
oxidation of DHA [54]. Thus, encapsulating DHA in NC
did not lead to an enhanced proliferation per se. Indeed,
it prevented the oxidation of DHA and the associated
inhibition of proliferation. The encapsulation of DHA
with VitE did not affect cell proliferation when com-
pared to the same experiments without NC since VitE
already fully protected free-DHA against oxidation. A
better protection of DHA in NC could be observed
when huge concentrations of DHA were used (50 and
100 μM) probably because where free-DHA at 50 or
100 μM could not be fully protected by a limiting con-
centration of VitE.
The mechanism by which secondary products of lipid
peroxidation retard or inhibit mammary cancer cell growth
processes in vitro and/or in vivo is not certain [53]. Oxy-
genated metabolites produced by lipid peroxidation are
capable of decreasing cell proliferation through damaging
cell membranes, by changing membrane lipid composition
and structure and/or cytoskeleton assembly [55]. These
modifications in the molecular architecture of the mem-
brane can lead to the inactivation of membrane transport
systems and/or membrane bound enzymes [56, 57].
Furthermore, secondary products of lipid peroxidation can
decrease tumor cell survival by inactivating DNA polymer-
ase reactions [58] forming intramolecular linkages between
biomolecules DNA, RNA, and proteins [59], and inhibiting
polyamine synthesis. Other studies reported that the
induction of apoptosis appears as the major mechanism
of action for the products of the peroxidation of PUFA
[15, 16, 60, 61]. Recently, it has been shown that the
cardiac anti-arrhythmic properties of DHA are due to
an oxygenated metabolite of DHA: 4-F4t-NeuroP [62].
We tested if this neuroprostane could be responsible for
the anti-proliferative effects of DHA and found that, even
if it does have some effect, this effect is less pronounced
than that of DHA+H2O2, suggesting that other oxygen-
ated metabolites are involved. Encapsulation of 4-F4t-
NeuroP prevented the proliferation-stimulating effects at
low doses of the free NeuroP, suggesting that this com-
pound can be further non-enzymatically metabolized.
Conclusion
In the present paper, we show that NC can prevent the
oxidation of encapsulated drugs delaying deteriorative
reactions and enhancing chemical stability under differ-
ent environmental conditions such as cancer. The poly-
ε-caprolactone (PεCL) nanocapsules designed for oral
route were successfully prepared to encapsulate the
PUFA in the oily core. This study shows that they effect-
ively protect PUFAs from oxidative degradation and re-
duced cellular effects following its lipophilicities. On the
other hand in the oxidative environment the NC are
destabilized and permit DHA oxidation. Thus the differ-
ence between the activities of DHA and its non-
enzymatic oxygenated metabolite in NC form could be
attributed to their difference in lipophilicities (log P) and
affinities for the NC oily core that further influences
their release rate in the cell medium. The encapsulation
process is thus a mean to protect and stabilize the en-
capsulation of drugs or fatty acids against premature
degradation that may occur before it reaches the target
after systemic administration.
Methods
Reagents and drugs
All reagents for culture cells were obtained from Life Tech-
nologies SARL (Cergy Pontoise Cedex, France). Epikuron®
170 (~70 % soy phosphatidylcholine) was a gift from Lucas
Meyer (Le Blanc Mesnil, France). Miglyol® 810 N oil
(capryc/caprylic triglyceride) was purchased from Hülls
(Frankfurt, Germany). The poly-ε-caprolactone (PεCL,
average 42,500 Da), Poloxamer®188, DHA, α-tocopherol
(vitamin E) and hydrogen peroxide (H2O2) were provided
by Sigma-Aldrich (St. Louis, MO) and the acetone was
purchased from Mallinckrodt chemicals (USA). Symplicity®
System (Millipore, Bedford, USA) was used to produce
Milli-Q water (18.2 MΩ), which was used to prepare nano-
capsules and all solutions for this study. The synthesis of
4(RS)-4F4t-neuroprostane was performed according to our
published procedure [47].
Fatty acid solutions
DHA and 4(RS)-4F4t-neuroprostane stock solutions (Fig. 5)
were prepared in ethanol at a concentration of 100 mM
and stored under a nitrogen atmosphere at − 20 °C. The
vitamin E stock solution was prepared in chloroform at
1 mM. The hydrogen peroxide stock solution was freshly
prepared in MilliQ water at 10 mM.
Nanocapsules preparation
Poly-ε-caprolactone (PεCL) nanocapsules (NC) were
prepared by preformed polymer deposition method
followed by solvent displacement as firstly described by
[42]. An organic solution was prepared with 60 mg PεCL
polymer dissolved in an acetone solution (10 mL) con-
taining 75 mg Epikuron®170, 250 μL Miglyol®810 N and
the different concentrations of PUFAs (see Fig. 4). This
organic solution was poured into the external aqueous
phase (20 mL) containing 75 mg Poloxamer®188 and the
mixture was kept under magnetic stirring for 10 min.
Solvents were removed under reduced pressure in a ro-
tary evaporator R-215 coupled to vacuum controller
(Büchi, Labortechnik AG, Switzerland) to render 10 mL
of aqueous colloidal NC suspension of each formulation.
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Characterization of PUFA-loaded nanocapsules
Size distribution
The Z-average hydrodynamic diameter of NC and popula-
tion polydispersity were determined by dynamic light scat-
tering (DLS) at 25 °C in Beckmann Coulter (Fullerton,
USA). Nanosizer N5Plus Analyser at 90° angle detector sig-
nals, and in a Malvern Instruments (Worcestershire, UK)
Zetasizer Nano PN3702 with non-invasive back-scattering
analysis at 173°, coupled in-line with the AsF4 equipment.
Samples were analyzed after 1:1000 dilution in Milli-Q
water. Measurements were performed in triplicate. Values
reported are the means ± standard deviation of at least
three different batches of each NC formulation.
Zeta potential
The zeta potential (ζ) was determined by Laser Doppler
Anemometry coupled to microelectrophoresis in a
Zetasizer Nano PN3702 equipment (Malvern Instru-
ments, Worcestershire, UK). The samples were ana-
lyzed after dilution (1:1000) in 1 mM NaCl. Both
measurements were performed in triplicate. Values re-
ported are the means ± standard deviation of at least
three different batches of each NC formulation.
Atomic force microscopy
NC samples were also analyzed by scanning-probe mi-
croscopy in atomic force mode (AFM). Analyses were
performed at atmospheric pressure, at room temperature,
on Dimension 3000 atomic force microscope monitored
by a Nanoscope IIIa controller (Digital Instruments, Santa
Barbara, CA, USA). A droplet (5 μL) of each NC sample
was deposited on mica, spread and dried with a stream of
argon. The images were obtained in tapping mode, using
commercial silicon probes, with a 228 μm-long cantilever,
75–98 kHz resonance frequencies, spring constants of
3.0–7.1 N/m and a nominal tip curvature radius of 5 nm.
The scan rate was 1 Hz. Dimensional analyses were
performed using the “section analyses” software of the
equipment. In order to observe the influence of the probe
on NC integrity, regions containing several NC were
initially imaged with a large scan size (20 μm). In order to
look for any oil leakage, zooming-in at smaller scale
(1–2 μm) was then performed on some selected NC,
which were then scanned three times. Images were
then zoomed-out and these NC were compared, in
size and occurrence of oil leakage, with their large-
scale NC neighbors. NC were also imaged 24 h after
the deposition on mica in order to get information
on their integrity with time before fractionation.
Asymmetrical flow-field-flow-fractionation analysis of
nanocapsules
The asymmetrical flow-field-flow-fractionation system
(AsF4) used was an AF2000 MT system (Postnova
Analytics, Landsberg, Germany), with Solvent degasser
PN7520 autosampler (PN5300 model, Postnova Analytics)
and Isocratic LC–Pump PN1130 (Postnova Analytics,
Landsberg). The channel had a 0.0350 cm thick spacer
and was 27.5 cm long (tip to tip) and 2 cm wide. A regen-
erated cellulose membrane having a nominal cut-off of
10 kDa was fixed over a porous frit wall. Samples diluted
in water (1:200) were injected (10–50 μL) and eluted with
particle- free Milli-Q water under a channel tip flow of
4.5–0.5 mL/min, for a duration of 35 min. The focusing
step consisted of a flow delivered by the injection port
of 4.2 mL/min for 2 min. The cross- flow gradient was
4–0 mL/min (35 min). After 35 min a tip flow of
0.5 mL/min was maintained for 20 min to clean up the
channel. The system was coupled with a variable
wavelength PN3211 ultraviolet spectrophotometric (UV)
detector (Postnova Analytics, Landsberg) using a deuter-
ium lamp set at 254 nm, with a PN3621 Multi Angle Laser
Light Scattering Detector/MALLS (Postnova Analytics,
Landsberg) and with a DLS detector in line in Zetasizer
PN3702 (Malvern Instruments, UK). The acquisition and
processing of data were performed using AF2000 Focus
Software Version 1.1.0.23. The geometric radius (Rg) of the
NC was calculated using the data from the 15 angles
analysis with MALLS detector by applying the coated
sphere model [63, 64]. The calculation of the geometric
diameter for spherical particles is given by the for-
mula Dg = Rg*0.775*2. DLS provides the Z-average
hydrodynamic diameter and hydrodynamic radius by
calculation and the MALLS gives the geometric diam-
eter (mean square root) calculated from the direct de-
termination of gyration radius. The ratio Rg/Rh allows
estimating the shape factor [46].
Cell culture experiments
Cell culture
Normal immortalized human breast epithelial cell line
(MCF-10A) [65] and human breast adenocarcinoma
cell line (MDA-MB-231) [66] were purchased from the
American Type Culture Collection (LGC Promochem,
Molsheim, France). MCF-10A were cultured routinely
in DMEM/Ham’s F-12 supplemented with 5 % horse
serum, 10 μg/mL insulin, 20 ng/mL epidermal growth
factor, 0.5 μg/mL hydrocortisone and 100 ng/mL chol-
era toxin. MDA-MB-231 cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM, 4.5 g/L D-
glucose, 584 mg/L L- glutamine and 3.7 g/L NaHCO3)
supplemented with 5 % fetal calf serum. Cells were
grown at 37 °C in a humidified atmosphere containing
5 % CO2. Medium was renewed every day. MCF10A
doubling time was 48 hrs vs. 24 hrs for MDA-MB-231
cells. Cells were routinely cultured without antibiotics,
and were passaged weekly with trypsin-EDTA when
attaining 80–100 % confluence.
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Assessment of cell proliferation
Cell proliferation was determined by the tetrazolium salt
assay with MTT reagent, [3-(4,5- dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide] as described previously [67,
68]. To minimize interference from serum (fetal bovine
serum for routine culture of MDA-MB-231 cells and horse
serum for routine culture of MCF10A cells), MCF10A cells
were adapted to MDA-MB-231 cells medium for 1 week
prior to experiments as previously described . MCF-10A
and MDA-MB-231 cells were seeded in 96-well plates at a
density of 5000 cells per well (15,000 cells/cm2). After
seeding, cells were incubated for 4 days in 200 μL medium
supplemented with increasing concentrations of DHA or
4F4t-NeuroP (0.3; 1; 3; 10; 30; 50; 100 μM as previously
used [20, 22] or DHA with anti-oxidant (1 μM VitE) or
pro-oxidant (1 μM H2O2). To observe antioxidant or oxi-
dant effect, solutions containing different concentration of
DHA with 1 μM VitE or with 1 μM H2O2 were separately
diluted in the media 20 min before application to cells in
96-well plates. In these conditions, DHA was added after
VitE or H2O2. The same protocol was used before encapsu-
lation. We previously described a strategy based on an eas-
ily accessible bicyclic precursor to obtain isoprostane
derivatives [69]. We applied this strategy to the synthesis of
the more complex 4(RS)-4-F4t-neuroprostane [47].
Several controls were included, which contained an
equivalent volume of the delivery vehicle (ethanol, chloro-
form, VitE-free, H2O2-free, or blank-NC).
After incubation for 4 days in the different conditions,
cells were washed out with PBS to remove the different
conditions media and further incubated for 60 min at 37 °C
in 200 μL culture medium containing 0.5 mg/mL MTT.
Metabolically active cells reduced MTT to purple formazan
crystals, which were then solubilized in 200 μL dimethyl-
sulfoxide (DMSO). The absorbance of each well was read
at 570 nm in a Spectramax 190 spectrophotometer
(Molecular Devices Corporation, Sunnyvale, CA).
For all experiments, products were prepared freshly
from stock solution and diluted with growth culture
medium. VitE, H2O2, ethanol and blank NC were evalu-
ated against the cells and no effects on cellular prolifera-
tion were observed at the tested doses compared to cell
proliferation in the original culture medium.
The relative cell proliferation (absorbance of test wells)
was expressed as a percentage of the control (line 100 %)
that was not treated with DHA (absorbance of control
wells without DHA or blank-NC). Mean values and stand-
ard deviation were obtained from the analysis of 5 wells,
and the experiments were repeated three times to calcu-
late the standard errors of the experiments.
Statistical analysis
All data are given as mean ± SEM. Statistical analyses,
Kruskal-Wallis non parametric test followed by Dunn’s
analysis were performed using GraphPad Prism® (Prism
5 for Mac OS X). A p value of 0.05 or less was consid-
ered as statistically significant.
Abbreviation
ζ: Zeta potential; 4F4T-NeuroP: 4(RS)-4-F4t-neuroprostane; AFM: Atomic force
miscroscopy; ALA: α-linolenic acid; AsF4: Asymmetrical flow-field-flow-fractionation
system; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; DLS: Dynamic
light scattering; H2O2: Hydrogen peroxide; MALLS: Multi-angle laser
light- scattering detector; MTT reagent: 3-(4,5- Dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide; NC: Nanocapsule; PεCL: Poly-ε-caprolactone;
PUFA: Dietary polyunsaturated fatty acids; Vitamin E: α-tocopherol.
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